Safwan Jaalouk, MD
Interventional Cardiology · Pensacola, FLNPI 1619977121
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $10,590 of the $16,476 with a category attached, or 64.3%. Medtronic accounts for 68.8% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $10,617 and has fallen 93.4% since, to $698 in 2025.
Across 146 payments — averaging $112.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$11K
- Abiomed$2K
- Abbott$2K
- Boston Scientific$564
- GE HealthCare$228
- Biotronik Inc.$131
- plus $783 from 17 others
Across 7 payments — averaging $1198.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$8K
What the payments were for
- Travel & lodging$10,59064%
- Food & beverage$5,87436%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 33 | $11,332 |
| Abiomed | 33 | $1,932 |
| Abbott | 25 | $1,506 |
| Boston Scientific | 14 | $564 |
| GE HealthCare | 4 | $228 |
| Biotronik Inc. | 2 | $131 |
| Edwards Lifesciences | 2 | $116 |
| Amgen | 6 | $90 |
| Pfizer | 6 | $89 |
| Merck | 1 | $85 |
| Cvrx, Inc. | 1 | $71 |
| Johnson & Johnson | 4 | $62 |
| Akcea Therapeutics, Inc. | 1 | $58 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $47 |
| Baxter Healthcare | 1 | $40 |
| Cook Medical LLC | 2 | $29 |
| Acist Medical Systems, Inc. | 1 | $18 |
| Penumbra, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$10,401
- Impella$1,245
- MitraClip$773
- CoreValve Evolut$151
- WATCHMAN Access System$136
- STINGRAY$125
- TRICLIP$123
- GENERAL - STRUCTURAL HEART$113
How this compares
$16,476 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $78,147 |
| Repatha SureclickEvolocumab | 25 | $30,568 |
| EntrestoSacubitril/Valsartan | 26 | $22,850 |
| JardianceEmpagliflozin | 18 | $15,744 |
| BrilintaTicagrelor | 14 | $8,822 |
| ClopidogrelClopidogrel Bisulfate | 319 | $4,938 |
| Atorvastatin Calcium | 144 | $1,802 |
| Metoprolol Succinate | 99 | $1,550 |
| Carvedilol | 93 | $973 |
| Rosuvastatin Calcium | 83 | $875 |
| Losartan Potassium | 74 | $735 |
| Nitroglycerin | 53 | $717 |
| Potassium Chloride | 39 | $687 |
| Amlodipine Besylate | 103 | $646 |
| Lisinopril | 87 | $594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $89 | $78,14778 claims |
| NovartisEntresto | $12 | $22,85026 claims |
| AstraZenecaBrilinta | $11 | $8,82214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Pensacola
- Rohit AminPensacola$560K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.